reports
Resmed Announces Participation in the Bank of America Global Healthcar...
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025 SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay w...
Medtronic Plc: 1 director
A director at Medtronic Plc sold 8,605 shares at 91.580USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Pr...
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of , a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute partners with clinicians, researchers, policymakers, and healt...
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adul...
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in projecting a significant rise in obstructive sleep apnea (OS...
Stryker Corp: 1 director
A director at Stryker Corp sold 1,785 shares at 393.070USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awar...
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs Milestones underscore Resmed’s leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its nasal cradle mask won two prestigious : Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed...
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors...
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company als...
Stryker to host investor day
Stryker to host investor day Portage, Michigan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host an Investor Day on Thursday, November 13, 2025, at 2:30 p.m. Eastern Time, in Mahwah, New Jersey. A live audio webcast of the session, along with a replay, will be accessible on Stryker’s official website at . The recording will be archived on the Investor Relations section of the site. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and se...
Stryker to participate in the 2025 Wells Fargo Securities Healthcare C...
Stryker to participate in the 2025 Wells Fargo Securities Healthcare Conference Portage, Michigan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2025 Wells Fargo Securities Healthcare Conference on Thursday, September 4, at the Encore Boston Harbor. Andy Pierce, Group President, MedSurg and Neurotechnology, and Jason Beach, Vice President, Finance and Investor Relations will participate in a Fireside Chat scheduled for 2:15 pm Eastern Time. A live audio webcast of the session, along with a replay, will be accessible on Stryker’s official website at . The ...
Moody's Ratings affirms Edwards Lifesciences at Baa2; revises outlook ...
Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. At the same time, we revised the outlook to positive from stable. The rating affirmation reflects our view that E...
Conmed Corp: 1 director
A director at Conmed Corp sold 598 shares at 52.450USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Stryker declares an $0.84 per share quarterly dividend
Stryker declares an $0.84 per share quarterly dividend Portage, Michigan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and ser...
Stryker reports second quarter 2025 operating results
Stryker reports second quarter 2025 operating results Portage, Michigan, July 31, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2025: Second Quarter Results Reported net sales increased 11.1% to $6.0 billionOrganic net sales increased 10.2%Reported operating income margin of 18.5%Adjusted operating income margin(1) increased 110 bps to 25.7%Reported EPS increased 7.0% to $2.29Adjusted EPS(1) increased 11.4% to $3.13 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures...
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 20...
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue incre...
Boston Scientific Corp: 1 director
A director at Boston Scientific Corp sold 2,901 shares at 106.990USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Edwards Lifesciences Corp: 1 director
A director at Edwards Lifesciences Corp sold 4,114 shares at 79.461USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Johnson & Johnson: 1 director
A director at Johnson & Johnson sold 19,137 shares at 163.549USD and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location: •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / ...
Stryker to announce financial results for its second quarter of fiscal...
Stryker to announce financial results for its second quarter of fiscal year 2025 Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at that day. The press release will include summary financial information for the company’s second quarter that ended June 30, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, July 31, 2025, to discuss its second quarter 2025 resu...
Moody's Ratings upgrades Stryker Corporation to A3; revises outlook to...
Moody's Ratings (Moody's) upgraded Stryker Corporation's (Stryker) senior unsecured notes to A3 from Baa1, its senior unsecured shelf registration to (P)A3 from (P)Baa1, and its long term issuer rating to A3 from Baa1. At the same time, we affirmed Stryker's Prime-2 short-term commercial paper ratin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.